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Abstract
Background: Although soy protein and its isoflavones have been reported to reduce the risk of
osteoporosis in peri- and post-menopausal women, most of these studies are of short duration (i.e.
six months). The objective of this study was to examine if one year consumption of soy-containing
foods (providing 25 g protein and 60 mg isoflavones) exerts beneficial effects on bone in
postmenopausal women.
Methods: Eighty-seven eligible postmenopausal women were randomly assigned to consume soy
or control foods daily for one year. Bone mineral density (BMD) and bone mineral content (BMC)
of the whole body, lumbar (L1-L4), and total hip were measured using dual energy x-ray
absorptiometry at baseline and after one year. Blood and urine markers of bone metabolism were
also assessed.
Results and Discussion: Sixty-two subjects completed the one-year long study. Whole body and
lumbar BMD and BMC were significantly decreased in both the soy and control groups. However,
there were no significant changes in total hip BMD and BMC irrespective of treatment. Both
treatments positively affected markers of bone formation as indicated by increased serum bone-
specific alkaline phosphatase (BSAP) activity, insulin-like growth factor-I (IGF-I), and osteocalcin
(BSAP: 27.8 and 25.8%, IGF-I: 12.8 and 26.3%, osteocalcin: 95.2 and 103.4% for control and soy
groups, respectively). Neither of the protein supplements had any effect on urinary
deoxypyridinoline excretion, a marker of bone resorption.
Conclusion: Our findings suggest that although one year supplementation of 25 g protein per se
positively modulated markers of bone formation, this amount of protein was unable to prevent
lumbar and whole body bone loss in postmenopausal women.
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Background
It is estimated by the year 2010, 35 million women in the
United States either will have osteoporosis or be at risk of
developing the disease if appropriate preventive measures
are not taken [1]. Aside from existing drug therapies, cer-
tain lifestyle and nutritional factors are known to reduce
the risk of osteoporosis [2-5]. Additionally, there are a
considerable number of women that would prefer dietary
supplements as an alternative/adjunctive to conventional
therapeutic options [5]. Examples of these alternative
therapies include the use of natural or plant-based sub-
stances such as soy isoflavones [6-13]. Soy isoflavones
have received considerable attention due to their estro-
gen-like properties on certain tissues such as bone, leading
some investigators [14,15] to refer to them as naturally
occurring selective estrogen receptor modulators
(SERMs).
Epidemiological data suggest that populations with high
intakes of soy, i.e. Asians, have a lower incidence of oste-
oporotic fractures [16,17]. Asian women typically con-
sume about 20 g of soy daily which provides
approximately 40 mg isoflavones [18,19]. However, lower
rates of fractures in these populations may not be fully
attributed to soy consumption as there are a number of
other confounding factors which can influence skeletal
health.
From the research point of view, there are a number of
animal studies which have shown that soy protein and/or
its isoflavones positively influence bone mineral density
(BMD) [8,20-26]. In terms of human studies, there are
limited numbers of trials that have examined the effects of
soy and its isoflavones on bone. Some of these clinical tri-
als [27-29] are of short duration varying between 3 to 6
months, making the findings questionable since periods
less than one year may not be sufficient to detect clinically
relevant changes in bone mass. Nonetheless, even the
findings of the few clinical studies of one to two year dura-
tion that have been conducted [30-34] are inconclusive.
For instance, Vitolins et al. [30] reported that daily con-
sumption of 25 g soy protein with 5, 42 or 58 mg isofla-
vones had no bone preserving effects in peri- and post-
menopausal women in a two-year study. Recent findings
from two groups [31,32] have shown similar effects of soy
protein and its isoflavones on bone. In contrast, other
studies have suggested that isoflavone-rich soy milk deliv-
ering 80 to 90 mg isoflavones [33] or soy products deliv-
ering 40 to 60 mg isoflavones on a daily basis [34] have
some bone protective effects.
The purpose of the present study was to examine the
effects of one-year supplementation of soy-based prod-
ucts containing 25 g protein and 60 mg isoflavones on
BMD, bone mineral content (BMC), serum and urinary
markers of bone turnover in postmenopausal women.
The rationale for choosing this amount of soy protein was
based on the average intake of Asians [18,19] and the rec-
ommended amount in the FDA approved health claim
[35].
Methods
Subjects
Postmenopausal women younger than 65 years who were
not on HRT or any prescription medications or herbal
supplements, including soy isoflavones, known to posi-
tively influence bone were recruited. Women with cancer,
liver disease, hypo- or hyperthyroidism, gastrointestinal
disorders, insulin-dependent diabetes mellitus, pelvic
inflammatory disease, and endometrial polyps were
excluded from the study. The study protocol was
approved by the Institutional Review Board at Oklahoma
State University. Subjects signed a consent form after
being provided with oral and written descriptions of the
study. A complete medical history was obtained from all
subjects before initiating the treatments. Subjects were
also given routine physical and gynecological examina-
tions. Subjects were independent living and were advised
to maintain their usual physical activity.
Study Design
Eighty-seven eligible postmenopausal women were ran-
domly assigned to one of two dietary treatments in a dou-
ble-blind parallel study. The dietary treatments consisted
of 25 g protein from soy products (donated by DrSoy
Nutrition Irvine, CA) or comparative control. The test
foods were in the form of a snack bar, drink mix or cereal
and were consumed daily for a period of one year. The soy
products were soy protein-based and delivered 60 mg iso-
flavones per day whereas the control regimen was devoid
of soy protein and isoflavones.
To ensure double-blinding, the study participants were
randomly assigned to one of the two treatments and the
study supplies were provided to the study participants in
unlabeled packages. Additionally, the identity of each
treatment was revealed to the investigators and research
personnel involved in the collection and analyses of the
data only after all analyses were completed. For this study
compliance was measured in two forms. First, study par-
ticipants were provided with customized calendars for
subjects to record how much of each of the cereal, the
snack bar, or the drink mix they consumed, if any. Second,
study participants were asked to return any unconsumed
foods to the study site so they could be tallied. The study
participants were advised by a registered dietitian to make
appropriate adjustments in their daily food consumption
to account for the additional energy and nutrients sup-
plied by the treatment regimen.Nutrition Journal 2005, 4:8 http://www.nutritionj.com/content/4/1/8
Page 3 of 9
(page number not for citation purposes)
Dietary assessment and anthropometric measurements
For each subject, medical and nutrition histories were
obtained at the beginning of the study. One-week food
frequency questionnaires were completed via interview by
a registered dietitian at the beginning and at the end of the
study. Nutrient analysis was performed using food analy-
sis software (Food Processor version 7.50, ESHA Research,
Salem, OR). Anthropometric data were collected at the
beginning, six months, and at the end of the study by a
single trained staff member, as described elsewhere [36].
Height and weight were used to calculate body mass index
(BMI). Abdominal and hip circumferences were used to
calculate waist-to-hip ratio.
Bone Density Assessments
Bone density was assessed at the beginning and at the end
of treatment using dual energy x-ray absorptiometry
(DXA; Hologic QDR-4500C, Waltham, MA) equipped
with appropriate software for whole body BMD and BMC.
Additionally, select regional sites, i.e. total hip and lum-
bar spine (L1-L4) were analyzed using high resolution
software. The intra- and inter- assay coefficients of varia-
tions were 3.4% and 5.1% and 2.5% and 4.7% for BMC
and BMD, respectively.
Gynecological exam and blood and urine collection
Study participants were provided with routine physical
and gynecological exams including a pap smear at base-
line and at the end of the study. A venous blood sample
was obtained after an overnight fast from each subject at
the beginning, six months, and at the end of the study for
various analyses. Blood samples were centrifuged at 2500
× g for 15 min at 4°C, serum samples were separated and
stored at -20°C until analyses. Each study participant col-
lected a 24-h urine specimen, excluding the first void, at
the beginning, after six months, and at the end of the
study. Urine volume was recorded and aliquots were
stored at -20°C for later analyses.
Analytical methods
To assess whether soy isoflavones modulate sex steroids
and their availability, serum levels of 17β-estradiol (E2),
estrone (E1), estrone sulfate, follicle stimulating hormone
(FSH), and sex hormone-binding globulin (SHBG) were
assessed as we have previously described [37] using radio-
immunoassay kits from Diagnostic Systems Laboratories
Inc. (Webster, TX). Serum bone-specific alkaline phos-
phatase (BSAP) activity, a specific marker of bone forma-
tion [38], was quantified by immunoassay in a microtiter
format (Metra Biosystems, Mountain View, CA). Alkaline
phosphatase (ALP), a nonspecific marker of bone forma-
tion [38], was determined colorimetrically using a com-
mercially available kit (Roche Diagnostics; Branchburg,
NJ) and analyzed with a Cobas-Fara II Clinical Analyzer
(Montclair, NJ). Additional serum biomarkers of bone
formation i.e. osteocalcin, insulin-like growth factor-I
(IGF-I), and IGF-binding protein-3 (IGFBP-3), which usu-
ally increases parallel to IGF-I, were also measured using
kits from Diagnostic Systems Laboratories Inc.
Urinary creatinine was measured colorimetrically with
commercially available kits (Roche Diagnostics) using a
Cobas Fara II clinical analyzer. Urinary deoxypyridinoline
(Dpd), a specific marker of bone resorption [39], was
measured by competitive enzyme immunoassay in a
microassay stripwell format (Quidel Corporation, Moun-
tain View, CA). The intra- and inter-assay CVs were 4.3%
and 4.6 %, and 6.5% and 8.6%, for creatinine and Dpd,
respectively.
Statistical Analyses
Data were analyzed using analysis of variance methods
with PROC MIXED in PC SAS (Version 8.2, SAS Institute,
Cary, NC) analyzing the main and interaction effects of
the two factors, treatment (soy protein or control) and
time (baseline or after treatment), using the SLICE option.
Since each subject was measured at baseline and after
treatment, a split plot (repeated measures) model was uti-
lized. The mean changes in endpoints for the soy protein
and control treatment groups were compared by analyz-
ing interaction effects of the two factors, treatment and
time, using the SLICE option. Data are reported as least
square mean ± standard error (SE); unless otherwise indi-
cated, P < 0.05 was regarded as significant.
Results
Baseline characteristics, anthropometric measurements, 
and dietary intake
Sixty-two of the 87 women completed the one year study
resulting in an attrition rate of approximately 29%. Rea-
sons for dropping from the study included medical condi-
tions preventing continuation in the study (2 women in
the soy group and 1 in the control group), starting HRT (1
woman in the soy group and 3 in the control group), non-
compliance (2 women in the soy group), dislike of the
volume or flavor of the food (3 women in the control
group), gastrointestinal side effects (2 women in the con-
trol group), food was causing headaches (1 woman in the
control group), and personal reasons (3 women in the soy
group and 2 in the control group). Five additional women
in the soy group decided to discontinue the study without
citing a particular reason.
Women in both treatment groups had similar baseline
characteristics (Table 1). Body weight and BMI signifi-
cantly increased in both treatment groups after one year of
supplementation. On average, women in the soy group
experienced a 1.6% increase in body weight, while a 3.3%
increase was observed in women in the control group.
Nonetheless, there was no significant change in waist toNutrition Journal 2005, 4:8 http://www.nutritionj.com/content/4/1/8
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hip ratio in either treatment group. In terms of dietary
intake, protein levels significantly increased in both treat-
ment groups, as expected, due to the study supplements.
Total caloric and carbohydrate intake increased in the
control group, but decreased in the soy group after one
year of supplementation (Table 2). No change in fat
intake was found in either group.
Bone mineral density and bone mineral content
Subjects in both the soy and control groups lost whole
body and lumbar BMD and BMC after one year, but no
change was observed in the total hip (Table 3). Whole
body BMD decreased by approximately 1.3% in both
treatment groups, while lumbar BMD decreased by 1.0%
in the soy group and 0.9% in controls (Figure 1). As
shown in Figure 2, whole body BMC decreased by 1.4%
and 1.0%, and lumbar BMC was reduced by 1.5% and
1.1% in the control and soy groups, respectively.
Although the change in whole body bone mineral area
(BMA) of the soy-treated group was increased and the
control group remained relatively unchanged, neither of
these alterations reached the level of statistical signifi-
cance (data not shown). The decrease in whole body BMD
of subjects on soy may have resulted from the small
increase in whole body area and a significant decrease in
BMC, whereas the change in BMD in the control group
was primarily a reflection of a decrease in BMC. Lumbar
and total hip BMA was unaltered by either dietary treat-
ment (data not shown).
Serum and urinary parameters of relevance to bone and 
calcium metabolism
Both dietary protein supplements significantly increased
serum markers of bone formation, i.e. osteocalcin, BSAP,
IGF-I and ALP (Table 4). However, IGFBP-3, which usu-
ally increases parallel to IGF-I, was only significantly
increased in the women consuming the soy products. Nei-
ther proteins had any effect on bone resorption as indi-
cated by urinary Dpd (Table 4).
Since there are some reports [40-42] indicating that soy
isoflavones may modulate sex steroids, we assessed serum
levels of FSH, E2, E1, and estrone sulfate. None of the treat-
ment significantly influenced these sex hormones (Table
Table 1: Subject characteristics at baseline and at the end of the study
Measures Control (n = 27) Soy (n = 35) Control vs Soy
Baseline Final %change Baseline Final %change p values
Trtmt Time Trtmt × Time
Age (yrs) 56 ± 5 53 ± 6
Years since menopause 6 ± 5 5 ± 5
Weight (kg) 71.7 ± 2.4 74.1 ± 2.4 +3.3 75.5 ± 2.2 76.7 ± 2.2 +1.6 0.334 <0.001 0.170
BMI (kg/m2) 27.3 ± 1.0 28.2 ± 1.0 +3.3 28.6 ± 0.9 29.0 ± 0.9 +1.4 0.436 <0.001 0.178
Waist to hip ratio 0.817 ± 0.014 0.815 ± 0.014 -0.2 0.787 ± 0.013 0.788 ± 0.013 +0.1 0.114 0.921 0.827
Values are least squares mean ± SE. BMI = body mass index.
No treatment effects were detected.
Table 2: Daily total energy and macronutrient intake at baseline and after one year supplementation of soy or control foods
Measures Control (n = 27) Soy (n = 35) Control vs Soy
Baseline Final Baseline Final p values
Trtmt Time Trtmt × Time
Total energy (kcal) 1577 ± 95b 1850 ± 96a 1827 ± 82a 1582 ± 84b 0.933 0.853 0.001
Protein (g) 64.2 ± 4.1c 87.8 ± 4.1a 75.8 ± 3.6b 87.3 ± 3.6a 0.241 <0.001 0.035
Carbohydrates (g) 207 ± 14bc 247 ± 14a 243 ± 12ab 202 ± 12c 0.752 0.938 <0.001
Total fat (g) 56.6 ± 4.8 59.0 ± 4.8 62.5 ± 4.1 57.0 ± 4.2 0.719 0.667 0.277
Calcium (mg) 796 ± 69 1168 ± 70 873 ± 60 1183 ± 62 0.459 0.003 0.777
Values are least squares mean ± SE.
Values were calculated from 7-day food frequency questionnaires and included the treatment regimen.
Within each row, values that do not share the same superscript letters are significantly (P < 0.05) different from each other. Soy food products on 
the average provided approximately 232 kcal, 25 g protein, 4.4 g fat, 25 g carbohydrates, 500 mg calcium and 60 mg isoflavones daily. Control food 
products on the average provided approximately 454 kcal, 25 g protein, 6 g fat, 77 g carbohydrates, 500 mg calcium and 0 mg isoflavones daily. Soy 
and control foods were donated by DrSoy Nutrition (Irvine, CA).Nutrition Journal 2005, 4:8 http://www.nutritionj.com/content/4/1/8
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5). However, soy but not control supplementation signif-
icantly decreased SHBG concentrations by 14.5%.
Discussion
The role of soy protein and its isoflavones in the mainte-
nance of health such as the prevention of cardiovascular
disease, certain types of cancer, and menopausal symp-
toms is now widely recognized [43-50]. In terms of bone,
there are animal [20-26] and human [27-34] studies that
have explored the role of soy in maintaining or increasing
bone mass. In general, animal studies have shown that
isoflavones in the context of soy protein have positive
effects on BMD [20-26]. The findings of clinical trials have
ranged from no significant changes [27-32] or a slight
increase [28,33,34] in BMD. Nonetheless, the bone pro-
tective effects of soy and/or its isoflavones are at best
inconclusive.
In the present study, the daily consumption of 25 g pro-
tein for one year irrespective of the source resulted in no
significant changes in hip BMD and BMC. Other investi-
gators [51,52] have reported that diets high in protein
were associated with higher BMD in femoral neck. We
Table 3: Effects of control and soy foods on bone mineral density (BMD) and bone mineral content (BMC)
Measures Control (n = 27) Soy (n = 35) Control vs Soy
Baseline Final Baseline Final p values
Trtmt Time Trtmt × Time
BMD, (g/cm2)
Whole body 1.050 ± 0.020 1.036 ± 0.0201 1.050 ± 0.018 1.036 ± 0.018 0.986 < 0.001 0.936
L1-L4 0.941 ± 0.026 0.933 ± 0.026 0.944 ± 0.022 0.934 ± 0.022 0.958 0.039 0.825
Hip, total 0.871 ± 0.021 0.870 ± 0.021 0.853 ± 0.018 0.852 ± 0.018 0.512 0.904 0.988
BMC, (g)
Whole body 2022 ± 58 1994 ± 58 2023 ± 49 2003 ± 49 0.944 < 0.001 0.465
L1-L4 53.631 ± 2.137 52.806 ± 2.137 54.737 ± 1.816 54.152 ± 1.816 0.662 0.018 0.681
Hip, total 57.532 ± 2.051 57.140 ± 2.051 57.278 ± 1.743 57.182 ± 1.743 0.967 0.738 0.839
Values are least squares mean ± SE. Lumbar spine (L1-L4).
No treatment effects were detected.
Mean percent change from baseline values in bone mineral  density (BMD) of the whole body, lumbar (L1-L4), and hip  after one year of supplementation with control or soy foods Figure 1
Mean percent change from baseline values in bone mineral 
density (BMD) of the whole body, lumbar (L1-L4), and hip 
after one year of supplementation with control or soy foods. 
Bars represent least square means ± SE.
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Mean percent change from baseline values in bone mineral 
content (BMC) of the whole body, lumbar (L1-L4), and hip 
after one year of supplementation with control or soy foods. 
Bars represent least square means ± SE.
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speculate that higher dietary protein may have a
protective effect on hip BMD over the long term. This
notion, however, seems somewhat paradoxical because
high protein diets, especially proteins rich in sulfur-con-
taining amino acids, are known to increase urinary
calcium that may result in accelerated bone loss [53].
Nonetheless, a counter-argument has been made that pro-
tein-associated hypercalciuria is due to enhanced intesti-
nal calcium absorption and not the breakdown of bone
[54,55].
Our findings do not support a bone protective role for soy
protein and its isoflavones at the level used in this study.
Whether higher amount of soy protein and/or its isofla-
vones can reverse bone loss remains to be illustrated.
Nonetheless, higher doses of soy protein with varying lev-
els of isoflavones have not consistently shown to exert
beneficial effects on bone. For instance, Gallagher et al.
[32] supplemented the diets of postmenopausal women
for nine months with 40 g soy protein delivering three lev-
els of isoflavones (0, 52, and 96 mg) but all three groups
experienced bone loss. On the other hand, six-month
studies by Potter et al. [28] and Alekel and colleagues [29]
reported positive effects of soy protein supplementation
on BMD. Potter et al. [28] showed that 40 g of soy protein
containing 90 mg isoflavones was able to attenuate lum-
bar spine (L1-L4) BMD, however, the same amount of
protein with 56 mg isoflavones had no such an effect.
Although Alekel et al. [29] suggested that 40 g soy protein
supplementation with 80 mg isoflavones was able to
attenuate bone loss from lumbar spine, women still lost
0.2% BMD in six months. Their data [29] imply that soy
protein or its isoflavones are incapable of increasing bone
mass in perimenopausal women.
As for an effect of soy isoflavones alone, Chen et al. [56]
recently reported that supplementing postmenopausal
women with soy isoflavones (40 and 80 mg/d) for one
year resulted in favorable increases in BMC of the hip in
women who are at least four years postmenopausal and
are of low body weight or have low levels of dietary cal-
cium. Similar to that study [56], the majority of the
Table 4: Effects of control and soy foods on serum and urinary markers of bone metabolism
Measures Control (n = 27) Soy (n = 35) Control vs Soy
Baseline 6 months Final Baseline 6 months Final P values
Trtmt Time Trtmt × Time
Serum
IGF-I (nmol/L) 17.9 ± 1.4b 20.5 ± 1.4a 20.2 ± 1.4a 13.3 ± 1.2c 16.8 ± 1.2ab 16.8 ± 1.2ab 0.023 < 0.001 0.693
IGFBP3 (ng/mL) 3833 ± 133 3934 ± 133 3904 ± 135 3442 ± 120b 3751 ± 120a 3622 ± 121a 0.087 0.005 0.252
Osteocalcin (ng/mL) 8.3 ± 2.1b 13.9 ± 2.1a 16.2 ± 2.2a 8.9 ± 1.9b 17.4 ± 2.0a 18.1 ± 2.0a 0.365 < 0.001 0.671
BSAP (U/L) 19.8 ± 1.2c 23.3 ± 1.2b 25.3 ± 1.2a 19.8 ± 1.1c 22.6 ± 1.1b 24.9 ± 1.1a 0.796 < 0.001 0.818
ALP (U/L) 57.4 ± 3.0c 65.9 ± 3.0b 74.0 ± 3.1a 56.6 ± 2.7c 69.1 ± 2.7b 74.3 ± 2.8a 0.798 < 0.001 0.499
Urine
Dpd (nmol/mmol creatinine) 5.3 ± 0.4 5.3 ± 0.4 4.9 ± 0.4 5.2 ± 0.3 5.4 ± 0.3 5.1 ± 0.3 0.888 0.234 0.744
Values are least squares mean ± SE. IGF-I = insulin-like growth factor-I; IGFBP-3 = insulin-like growth factor binding protein-3; BSAP = bone-specific 
alkaline phosphatase; ALP = alkaline phosphatase; Dpd = deoxypyridinoline.
Within each row, values that do not share the same superscript letters are significantly (P < 0.05) different from each other.
Table 5: Effects of control and soy foods on on sex hormones
Measures Control (n = 27) Soy (n = 35) Control vs Soy
Baseline 6 months Final Baseline 6 months Final P values
Trtmt Time Trtmt × Time
FSH (mIU/mL) 41.0 ± 3.8 37.5 ± 3.8 36.4 ± 3.8 44.8 ± 3.4 47.6 ± 3.4 43.2 ± 3.4 0.143 0.195 0.235
E2 (pg/mL) 9.9 ± 4.1 12.3 ± 4.1 8.8 ± 4.2 12.7 ± 3.7 19.5 ± 3.7 17.7 ± 3.8 0.120 0.314 0.690
Estrone (pg/mL) 14.3 ± 4.3 21.9 ± 4.3 13.9 ± 4.4 19.6 ± 3.8 22.0 ± 3.9 22.4 ± 3.9 0.283 0.290 0.448
Estrone sulfate (ng/mL) 1.2 ± 0.4 1.9 ± 0.4 1.1 ± 0.4 1.8 ± 0.4 2.0 ± 0.4 1.9 ± 0.4 0.264 0.309 0.552
SHBG (nmol/L) 87.1 ± 9.2 81.3 ± 9.2 76.3 ± 9.3 105.3 ± 8.2 88.2 ± 8.2 90.0 ± 8.3 0.264 0.002 0.355
Values are least squares mean ± SE. FSH = follicle stimulating hormone; E2 = 17β-estradiol; SHBG = sex hormone-binding globulin.
No treatment effects were detected.Nutrition Journal 2005, 4:8 http://www.nutritionj.com/content/4/1/8
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women in our present study were four or more years post-
menopausal; however, our study participants had
adequate calcium intakes and did not have low body
weights. It is possible that this difference in the nutrition
status of the study participants between the two studies
may be responsible for the discrepancy in the observed
effects on bone.
As far as which of the many isoflavones in soy is responsi-
ble for the effects on bone, to date, the most convincing
data on the effect of a single isoflavone, genistein, on
bone have been reported in a one-year study by Morabito
and colleagues [57]. They demonstrated that both genis-
tein at a dose of 54 mg/d and HRT increased BMD in early
postmenopausal women. In that study [57], genistein sig-
nificantly increased BMD of the femoral neck by 3.6% and
lumbar spine by 3.0% while HRT increased femoral neck
and lumbar spine BMD by 2.4 and 3.8%, respectively.
These authors [57] suggested that genistein reduces bone
resorption markers and enhances new bone formation
parameters resulting in a net gain of bone mass. Isolated
isoflavones derived from other sources such as red clover
have also been found to positively affect bone. For exam-
ple, Clifton-Bligh and colleagues [58] reported that clo-
ver-derived isoflavones at doses of 57 and 85 mg
isoflavones/day were able to significantly increase BMD of
the proximal radius and ulna by 4.1 and 3%, respectively
after 6 months. Similarly, Atkinson et al. [59] showed that
red-clover derived isoflavones (26 mg biochanin A, 16 mg
formononetin, 1 mg genistein, and 0.5 mg daidzein)
slowed the loss of lumbar spine BMC and BMD. These
data suggest that isoflavones from sources other than soy,
also have osteoprotective effects.
In the present study, biomarkers of bone formation, i.e.
osteocalcein, IGF-I, and BSAP were all significantly ele-
vated in both groups. However, the specific marker of
bone resorption, urinary Dpd, was not altered. A number
of clinical studies have evaluated the effects of soy protein
with its isoflavones on bone biomarkers. Overall, the
effects of soy and/or its isoflavones have produced no
consistent effects on biomarkers of bone turnover. For
instance, biomarkers of bone formation have been
reported to either increase [60,61] or not change [29,62]
as result of soy supplementation. Similarly, biomarkers of
bone resorption have been reported to decrease [62-64],
not change [61] or even increase [60]. We have previously
reported that 40 g of soy protein providing 90 mg of iso-
flavones/day reduced Dpd in postmenopausal women
not on HRT [62]. In the present study, participants were
asked to consume a lower amount of soy protein (only 25
g providing 60 mg of isoflavones/day). It is possible that
the reduced dose of soy in this study may have
contributed to the lack of effect on bone resorption (as
assessed by Dpd excretion) and that a dose-response study
may be justified in order to achieve both increases in
markers of bone formation and reductions in markers of
bone resorption. Nevertheless, the positive changes in
biomarkers of bone formation in the present study have
not translated to increases in BMD and BMC. Whether the
positive effects of protein supplementation on bone
biomarkers would translate to better bones needs to be
assessed in a longer term study.
Although in this study, soy supplementation for one year
did not produce any estrogenic effects as assessed by circu-
lating sex hormone levels, it did decrease SHBG concen-
trations Decreases in SHBG result in increases in the
availability of circulating estrogens [65]. Thus, soy
supplementation may have increased the availability of
estrogens without affecting actual concentrations. How-
ever, this is speculative and measurement of bioavailable
estradiol is necessary to confirm this statement.
From the findings of our study and the collective review of
existing literature, it is too early to state whether soy pro-
tein or its isoflavones can be substituted for estrogen in
preventing the bone loss induced by ovarian hormone
deficiency. Future studies are needed to address numerous
questions including but not limited to whether: 1) isofla-
vones independent of soy protein can prevent ovarian
hormone deficiency-associated bone loss; 2) consump-
tion of soy containing food or intake of isoflavones on a
daily basis is necessary to observe the expected beneficial
effects on bone or simply intermittent use will produce
the same results; 3) the effect of soy protein or its isofla-
vones on bone is transitory; and 4) the combination of
soy isoflavones and lower doses of antiresorptive agents
can prevent postmenopausal bone mineral loss. As these
and other questions are answered, the efficacy of soy pro-
tein and its isoflavones as alternative and/or adjunctive
treatments for postmenopausal osteoporosis can be
determined.
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